Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 51 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
501 17.6 months Metastatic prostate cancer 4 Biologic therapy
Chemotherapy
Duke Comprehensive Cancer Center United States 10/2008
Treatment Details: Patients: This phase I-II study involved 31 patients with metastatic, castration-resistant prostate cancer. The median age was 68, ranging from 50 to 81 years of age. Most (81%) had bone m
 
502 17.6 months GBM 3 Radiation
UCLA School of Medicine United States 11/2007
Treatment Details: Patients: This phase I study involved 33 patients with glioblastoma multiforme. The median age of these patients was 51, ranging from 23-72 years old. Twenty-one patients were men and twe
 
503 17.6 months Advanced metastatic colorectal cancer 4 Chemotherapy
Kyoto University Graduate School of Medicine Japan 2/2004
Treatment Details: Patients: This phase II study involved 56 patients with advanced/metastatic colorectal cancer. Treatment: Treatment consisted of the chemotherapy drug, capecitabine (xeloda). Toxicity:
 
504 17.6 months Advanced or metastatic colorectal cancer 4 Chemotherapy
Kyoto University Graduate School of Medicine Japan 2/2004
Treatment Details: Patients: This phase II study involved 56 patients with advanced/metastatic colorectal cancer. Treatment: Treatment consisted of the chemotherapy drug, capecitabine (xeloda). Toxicity:
 
505 17.6 months Advanced castration-resistant prostate cancer 5 Chemotherapy
University of Southern California Norris Comprehensive Cancer Center United States 8/2013
Treatment Details: Patients: This phase 3 study involved advanced castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A had 496 patients with a median age
 
506 17.6 months Castration-resistant prostate cancer 5 Chemotherapy
Hormone
University of Ulsan College of Medicine Korea 5/2014
Treatment Details: Patients: This phase 3 study involved 33 castration-resistant prostate cancer patients who had received prior docetaxel-based chemotherapy. The median patient age was 67 years (range: 52-8
 
507 17.5 months NHL 5 Biologic therapy
Chemotherapy
Hormone
Memorial Sloan-Kettering Cancer Center United States 3/2015
Treatment Details: Patients: This phase 2 study involved 30 elderly relapsed or refractory diffuse large B-cell lymphoma patients who were previously treated. The median patient age was 76 years (range of 69
 
508 17.5 months Metastatic Melanoma 5 Biologic therapy
Immunotherapy
Dana-Farber Cancer Institute United States 11/2014
Treatment Details: Patients: This phase 2 study involved metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 123 patients with a median age of 61 years; 69.
 
509 17.5 months Metastatic or primary breast cancer 4 Chemotherapy
University Hospital of Vienna Austria 8/2002
Treatment Details: Patients: This Phase I/II trial involved 33 women with metastatic or primary breast cancer. Treatment: The treatment consisted of two drugs epidoxorubicin and docetaxel (taxotere). Ma
 
510 17.5 months Metastatic rcc 4 Immunotherapy
Beth Israel Deaconess Medical Center United States 1/2005
Treatment Details: Patients: This Phase III study involved a total of 192 patients with metastatic renal cell carcinoma. Patients were divided into two groups of 96 patients each. Each group was administered
 
Page 51 of 187  | Previous Page  | Next Page